Recital 9, Regulation (EU) 2022/20

In forcesince 7 Jan 2022

To maintain a proportionate distribution of work between Member States over time, it should be possible, upon request of the original safety assessing Member State, to transfer the role of safety assessing Member State when the original safety assessing Member State is no longer a Member State concerned in any clinical trial involving the use of an active substance or when its workload related to the role of safety assessing Member State becomes disproportionately high in comparison to the workload of the other Member States. However, it is necessary to ensure the continuity of the safety assessment at any time during the re-selection process of the safety assessing Member State.